title: Genetic engineering of death ligands for improvement of therapeutic activity.
authors.affiliation: Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany.
authors.forename: Jeannette
authors.initials: J
authors.lastname: Gerspach
authors.forename: Britta
authors.initials: B
authors.lastname: Schneider
authors.forename: Nicole
authors.initials: N
authors.lastname: Müller
authors.forename: Tina
authors.initials: T
authors.lastname: Otz
authors.forename: Harald
authors.initials: H
authors.lastname: Wajant
authors.forename: Klaus
authors.initials: K
authors.lastname: Pfizenmaier
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D016923:Cell Death / Q000187:drug effects; D053222:Fas Ligand Protein / Q000627:therapeutic use; D005818:Genetic Engineering / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000473:pathology; D011355:Prodrugs / Q000494:pharmacology / Q000627:therapeutic use; D055503:Protein Multimerization / Q000187:drug effects; D055550:Protein Stability / Q000187:drug effects; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000627:therapeutic use; D048069:Tumor Necrosis Factors / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D053222:Fas Ligand Protein; D011355:Prodrugs; D011993:Recombinant Fusion Proteins; D053221:TNF-Related Apoptosis-Inducing Ligand; D048069:Tumor Necrosis Factors